The authors concluded that the impact of post-myocardial infarction depression interventions on physical healthrelated quality of life (HRQOL) was modest, but treatment can improve mental HRQOL in a significant way. The authors' conclusions reflect the evidence presented, but the small number of included studies, small samples and variation between studies mean the conclusions should be viewed with caution.
Study selection
Randomised controlled trials (RCTs) that evaluated depression treatment in patients who had a myocardial infarction or acute coronary syndrome and recorded positive on a depression screener were eligible for inclusion. Depression treatment could include pharmaceuticals and/or psychotherapy. Outcomes of interest were health-related quality of life or self-rated health. Studies had to include at least six months follow-up.
Interventions included sertraline (50mg to 200mg), stress management, counselling, cognitive-behavioural therapy and phone counselling. Comparator groups were usual care or placebo. Most of the participants in the included studies were defined as being diagnosed with myocardial infarction or unstable angina. Some studies included participants who underwent bypass surgery. Measurement of depression was conducted using various instruments or through self report. HRQoL was measured using Short-form (SF) 12 or 36, Clinical Global Impression Improvement Scale (CGI-I) or Ladder of Life scale and were measured at baseline (except for one study) and at six months follow-up. Time of depression screening varied widely between studies (details reported in the review). Studies were published between 2003 and 2009. Most of the studies were conducted in North America.
Sensitivity analyses excluded low-quality studies (low quality was not defined). Subgroup analysis explored effects of treatment on HRQoL by instrument, comparator groups and cardiac condition as well as the effects of different methods of treatment of depression on HRQoL.
Results of the review
Five RCTs (2,105 participants) were included in the review. All five studies reported adequate randomisation. Outcome assessors were blinded in three RCTs. Losses to follow-up ranged from 10% to 21%. Treatment for depression of cardiac patients resulted in a statistically significant improvement compared to comparison groups at six months for mental HRQoL scores (SMD -0.29, 95% CI -0.38 to -0.20, I 2 =0%; five RCTs). Sensitivity analyses and subgroup analyses did not significantly alter the results.
Treatment for depression had a small but significant impact on physical HRQoL scores (SMD -0.14, 95% CI -0.24 to -0.04, I 2 =15%). However, when analyses were conducted adjusting for surgical intervention, treatment appeared to have little impact on HRQoL (data not reported). Analyses that removed one study with a placebo group resulted in the overall result showing no significant effect between groups. Subgroup analysis found that combined (two RCTs) and psychological (two RCTs) approaches to depression treatment had no significant impact on physical health.
